ClinicalTrials.gg
Not yet recruitingNCT06743113Updated Nov 2, 2026

Hypoxic Red Blood Cells in Sickle Cell Anemia

An interventional study of Hemanext ONE System and Conventional RBCs in Sickle Cell Anaemia, Sickle Cell Anemia Crisis and Sickle Cell Anemia in Children, sponsored by Hemanext. Not yet recruiting at 5 sites in United States. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Hemanext · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
205th of 559
48 · median 31
Started
2026
with 28 others
No phase
165 of 733
36 open now
Primary completion
2029-04
later than 138 of 182 live
Registered
679th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 205th largest by planned enrollment of the 559 interventional ones that give a count, is one of 29 that started in 2026, is one of 165 with no phase, reaches primary completion later than 138 of the 182 other live ones, and was the 679th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 7 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.

Read the detailed description

In this Direct-to-Phase II study, Hemanext Inc. will carry out a prospective, multi-center, single-blind, randomized, cross-over study in patients with Sickle Cell Anemia, comparing the efficacy of transfusion of hypoxic red blood cells (HRBCs) to transfusions with conventional RBCs. The primary efficacy objective is to demonstrate an increase in %HbA between red cell exchange transfusions (RCE) of HRBCs compared to conventional RBCs. The increases in %HbA (normal Hb) from RCE will be accompanied by a concomitant decrease in sickle Hb (%HbS). The persistence of %HbA will allow for a decrease in the volume of RBCs transfused with an overall decrease in the number of units consumed, which in turn can result in an increase in time (number of days) between transfusions.

03

Conditions studied

  • Sickle Cell Anaemia
  • Sickle Cell Anemia Crisis
  • Sickle Cell Anemia in Children
  • Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 7 years of age;
  2. Are able to provide , and assent as applicable, to participate in the study;
  3. Diagnosis of Sickle Cell Anemia (SCA) (HbSS, HbSβ0 thalassemia) with participation in a chronic transfusion program and have undergone regular transfusions during at least 6 months prior to Screening;
  4. Have had an average interval of at least 14 days between RBC transfusions over the past 6 months;
  5. If on iron chelation therapy, have been on a stable dose for ≥3 months prior to screening;

Exclusion criteria

Exclusion Criteria:

  1. Are not exclusively transfused at the site;
  2. Have a diagnosis of HbSC disease, HbSβ+ thalassemia or another SCD variant (excluding HbSS and HbSβ0 thalassemia)
  3. Are routinely transfused with washed, packed RBC units;
  4. Have received inducers (e.g. erythropoietin) in the 30 days prior to Screening;
  5. Are currently being evaluated for gene therapy;
  6. Have any pulmonary, cardiovascular, endocrine, hepatic, gastrointestinal, renal, infectious, immunological (including significant allo- or auto-immunization) disease, considered not adequately controlled prior to the study;
  7. Are a female of who is pregnant or planning to become pregnant in the next 14 months;
  8. Have a history of allo-immunization that cannot be managed by the local blood bank;
  9. Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;
  10. Is a ward of the state, prisoner, or transient
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Treatment A (Hypoxic RBCs)

    Transfusion of hypoxic red blood cells manufactured with Hemanext ONE system

    Device: Hemanext ONE System

  • Active comparator
    Treatment B (Conventional RBCs)

    Transfusion of conventional red blood cells

    Device: Conventional RBCs

Interventions

  • DeviceHemanext ONE System

    Hypoxic red blood cells

  • DeviceConventional RBCs

    Conventional red blood cells

06

What researchers measure

Primary outcomes

  1. %HbA Rate of Decline

    The primary objective is to evaluate the decreased rate of decline of %HbA between post-transfusion RCE and the subsequent pre-transfusion RCE over 6 transfusion cycles in the hypoxic RBC group compared to the conventional group.

    Time frame: Through study completion, an average of 14 months

Secondary outcomes

  1. Volume of blood transfused

    The mean volume of blood per patient transfused with hypoxic RBCs and with standard RBC units will be analyzed and compared

    Time frame: Through study completion, an average of 14 months

  2. HgbS Rate of Increase

    Average rate of increase of the HgbS measurement between automated red cell exchange (RCE) of hypoxic RBCs compared to conventional RBCs.

    Time frame: Through study completion, an average of 14 months

  3. Incidence rate of vaso-occlusive crisis.

    Incidence rate of vaso-occlusive crisis events through the duration of the study

    Time frame: Through study completion, an average of 14 months

  4. Incidence rate of acute chest syndrome

    Incidence rate of acute chest syndrome events accompanied by fever and/or respiratory symptoms through the duration of the study

    Time frame: Through study completion, an average of 14 months

  5. Duration (days) of any hospitalization for vaso-occlusive crisis

    Mean duration (days) of any hospitalization for vaso-occlusive crisis

    Time frame: Through study completion, an average of 14 months

  6. Intravascular hemolysis

    Level of intravascular hemolysis (measured with free plasma hemoglobin) between each procedure, before and after each Red Cell Exchange.

    Time frame: Through study completion, an average of 14 months

  7. Serum ferritin

    Mean change from baseline in serum ferritin

    Time frame: Through study completion, an average of 14 months

  8. Changes in hepatic iron content

    Mean changes in hepatic iron content

    Time frame: Through study completion, an average of 14 months

  9. Change in QoL

    Mean change in QoL, as measured by validated QoL questionnaires

    Time frame: Through study completion, an average of 14 months

  10. Total hemoglobin before and after RCE

    Mean change before and after transfusions of hypoxically stored RBCs compared to that with conventionally stored RBCs.

    Time frame: Through study completion, an average of 14 months

  11. Total hematocrit before and after RCE

    Mean change before and after transfusions of hypoxically stored RBCs compared to that with conventionally stored RBCs.

    Time frame: Through study completion, an average of 14 months

  12. Red Cell Exchange events

    Mean number of RCE events over the course of the study

    Time frame: Through study completion, an average of 14 months

  13. Safety assessment

    Frequency of adverse event reactions and device deficiencies over the course of the study

    Time frame: Through study completion, an average of 14 months

Other outcomes

  1. Hemoglobin increment from each transfusion

    The hemoglobin increment from each transfusion will be determined by calculating the difference between the patient's post-transfusion and pre-transfusion hemoglobin. It will then be corrected for estimated patient blood volume and the amount of Hb transfused

    Time frame: Through study completion, an average of 14 months

07

Study locations

5 sites
  • New England Sickle Cell Institute, University of Connecticut
    Farmington, Connecticut 06030, United States
    • Biree Andemariam, MD · Contactandemariam@uchc.edu · 860-679-2100
    • Biree Andemariam, MD · Principal investigator
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
    • Ross Fasano, MD · Contactross.fasano@emory.edu · 404-727-5910
    • Ross Fasano, MD · Principal investigator
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    • Sally A Campbell-Lee, MD, FCAP, CABP · Contactscampbe@uic.ed · 312-996-3150
  • John Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
    • Elizabeth Crowe, MD, PhD · Contactecrowe3@jhmi.edu · 443-287-6854
    • Elizabeth Crowe, MD, PhD · Principal investigator
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15260, United States
    • Olubusola B Oluwole, MD · Contactoluwoleob2@upmc.edu · (412) 586-9875
    • Olubusola B Oluwole, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2029, 28 months later.

Of 173 interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 28 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 19, 2024
StartEst.
Nov 30, 2026was Sep 2026
Primary completionEst.
Apr 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Nov 30, 2026
Nov 2, 2026
Sponsor
Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Sep 1, 2026→Nov 30, 2026
    Sponsor Collaborators added: University of Illinois Chicago; collaborators removed: University of Illinois at Chicago
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06743113
Lead sponsor
Hemanext
Collaborators
Emory University, University of Connecticut, University of Pittsburgh Medical Center, Johns Hopkins University, University of Illinois Chicago, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Nov 30, 2026 (estimated)
Primary completion
Apr 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Jill Bagdasarian
Contact
jill.bagdasarian@hemanext.com
(781) 301-7474
Biree Andemariam, MD
principal investigator · New England Sickle Cell Institute, University of Connecticut
Laurel Omert, MD, FACS
principal investigator · Hemanext Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion